Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 351 to 355 of 355

Sort by

Type: GuidanceRemove Type: Guidance filter
Type: Quality standardRemove Type: Quality standard filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter
Guidance programme: Clinical guidelinesRemove Guidance programme: Clinical guidelines filter
Guidance programme: Interventional procedures guidanceRemove Guidance programme: Interventional procedures guidance filter
Guidance programme: Diagnostics guidanceRemove Guidance programme: Diagnostics guidance filter
Guidance programme: Highly specialised technologies guidanceRemove Guidance programme: Highly specialised technologies guidance filter
Guidance programme: Public health guidelinesRemove Guidance programme: Public health guidelines filter
Guidance programme: Antimicrobial prescribing guidelinesRemove Guidance programme: Antimicrobial prescribing guidelines filter
Guidance programme: Cancer service guidelinesRemove Guidance programme: Cancer service guidelines filter
Guidance programme: Medicines practice guidelinesRemove Guidance programme: Medicines practice guidelines filter
Guidance programme: Safe staffing guidelinesRemove Guidance programme: Safe staffing guidelines filter
Guidance programme: Social care guidelinesRemove Guidance programme: Social care guidelines filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]	Technology appraisal guidance	TBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]	Technology appraisal guidance	17 July 2024
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]	Technology appraisal guidance	TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	7 August 2024
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]	Technology appraisal guidance	23 October 2024

Results per page

10
25
50
All